PDCD1 and breast carcinoma: In the EMT6 breast cancer model (Figure 2E), where PD-1 therapy has limited efficacy, both 0.3 mg/kg and 1 mg/kg mAWT020 treatment demonstrated significantly better suppression of tumor growth than αmPD1 or the combination therapy of αmPD1 and HSA-IL-2c.